Skip to search formSkip to main contentSkip to account menu

belatacept

Known as: CD152 antigen, CTLA4-Ig 
National Institutes of Health

Related topics

Related topics

8 relations

Narrower (3)

BMS224818CTLA-4-IgLEA29Y
CTLA4 protein, humanbelatacept 250 MG Injection [Nulojix]belatacept single use injectioncytotoxic T-lymphocyte antigen 4

Broader (1)

abatacept

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
APVO210: A Bispecific Anti-CD86-IL-10 Fusion Protein (ADAPTIR™) to Induce Antigen-Specific T Regulatory Type 1 Cells
IL-10 is a potent immunosuppressive cytokine that promotes the differentiation of tolerogenic dendritic cells (DC-10), and the… 
Review
2015
Review
2015
Does belatacept improve outcomes for kidney transplant recipients? A systematic review
Belatacept was intended to provide better outcomes for kidney transplant (KT) recipients by allowing minimization/withdrawal of… 
Review
2012
Review
2012
Targeting the B7 Family of Co-Stimulatory Molecules
As more patient data is cross-referenced with animal models of disease, the primary focus on Th1 autoreactive effector cell… 
2011
2011
Immunomodulatory effects induced by cytotoxic T lymphocyte antigen 4 immunoglobulin with donor peripheral blood mononuclear cell infusion in canine major histocompatibility complex-haplo-identical…
BACKGROUND AIMS. Previously, cytotoxic T lymphocyte antigen 4 (CTLA4) immunoglobulin (Ig) has been shown to allow sustained… 
Review
2007
Review
2007
The blockade of T-cell co-stimulation as a therapeutic stratagem for immunosuppression: Focus on belatacept
The development of immunosuppressive drugs has in recent years been focused on prevention of acute rejection. This has led to an… 
Review
2006
Review
2006
Pharmacogenomics and lung transplantation: clinical implications
under-immunosuppression, with loss of the graft, and over-immunosuppression, with infection and lymphoproliferative disease as… 
Highly Cited
2002
Highly Cited
2002
Effect of administration of CTLA4-Ig as protein or cDNA on corneal allograft survival.
PURPOSE To examine the role of the CD28-CD80-CD86 pathway of T-lymphocyte costimulation in corneal allograft rejection and the… 
2000
2000
Blockade of the B7‐CD28 Pathway by CTLA4–Ig Counteracts Rejection and Prolongs Survival in Small Bowel Transplantation
Allograft rejection involves T‐cell activation, requiring T‐cell receptor interactions with major histocompatibility complex (MHC… 
Highly Cited
1996
Highly Cited
1996
CTLA4-Ig plus bone marrow induces long-term allograft survival and donor specific unresponsiveness in the murine model. Evidence for hematopoietic chimerism.
Allograft rejection is dependent on T cell activation, which requires both the engagement of the T cell receptor by antigen in… 
1996
1996
Immunosuppression with monoclonal antibodies and CTLA4-Ig after myoblast transplantation in mice.
Various combinations of monoclonal antibodies specific for lymphocyte cell surface antigens and a recombinant molecule (CTLA4-Ig… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)